NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
12/14/2019
Back to search
Official data from USPTO
PRIMUS PHARMACEUTICALS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
PRIMUS PHARMACEUTICALS
ST13
US500000077622816Class
5
Filing
77622816
Registration
3704515
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
28
Latest update
04/30/2025
Trademark type
Word
Nice classes
5
Filing date
11/26/2008
Registration date
11/03/2009
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/14/2019
Last transaction
04/30/2025
Responsible office
United States Patent and Trademark Office
Status code
800
Official register
Principal Register
First use anywhere
02/16/2004
First use in commerce
02/16/2004
Drawing code
4
Owner type
03
Owner location
Scottsdale, AZ
Examiner
EISINGER,REBECCA MILES
Law office
L20
Current location
GENERIC WEB UPDATE
Holders and representatives
Holders
Primus Pharmaceuticals, Inc.
Representatives
Monica L. Dias Frost Brown Todd LLC
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Medical foods for use in the dietary management of patients with osteoarthritis; medicated topical prescription preparations having anti-inflammatory properties; medicated topical prescription preparations having anti-infective properties; medicated topical prescription preparations having anti-inflammatory and anti-infective properties; medicated topical prescription preparations in the nature of anti-inflammatories and anesthetics for the treatment of dermatosishemorrhoids and other skin conditions; medical foods for use in the dietary management of patients at risk or with low bone densityosteopeniaosteoporosis; pharmaceutical preparations for the prevention or treatment of low bone densityosteopeniaosteoporosis; drug delivery agent consisting of compounds that facilitate the delivery of a wide range of pharmaceuticals; medical foods for use in the dietary management of patients with osteoarthritisrheumatoid arthritisother forms of arthritis or inflammatory diseases; pharmaceutical preparations for the treatment of osteoarthritisrheumatoid arthritisother forms of arthritis or inflammatory diseases; prescription productsprescription vitamins and prescription drugs for treating osteoarthritisdermatologicalocular and rheumatological diseases and conditions; medical foods for use in the dietary management of patients with osteoarthritisdermatologicalocular and rheumatological diseases and conditions
Publications
History of USPTO decisions and trademark events.
28 publications found
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
12/14/2019
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
12/14/2019
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
12/14/2019
E89R
TEAS SECTION 8 & 9 RECEIVED
11/01/2019
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
11/03/2018
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
12/29/2015
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
12/29/2015
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
12/29/2015
E815
TEAS SECTION 8 & 15 RECEIVED
10/29/2015
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
04/29/2013
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
04/29/2013
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
10/31/2011
R.PR
REGISTERED-PRINCIPAL REGISTER
11/03/2009
PUBO
PUBLISHED FOR OPPOSITION
08/18/2009
NPUB
NOTICE OF PUBLICATION
07/29/2009
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
07/15/2009
ALIE
ASSIGNED TO LIE
07/15/2009
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/06/2009
XAEC
EXAMINER'S AMENDMENT ENTERED
07/06/2009
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
07/06/2009
GNEA
EXAMINERS AMENDMENT E-MAILED
07/06/2009
CNEA
EXAMINERS AMENDMENT -WRITTEN
07/06/2009
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
02/27/2009
GNRT
NON-FINAL ACTION E-MAILED
02/27/2009
CNRT
NON-FINAL ACTION WRITTEN
02/27/2009
DOCK
ASSIGNED TO EXAMINER
02/25/2009
NWAP
NEW APPLICATION ENTERED
12/01/2008
Continuous trademark protection
Get notified about every new filing that threatens PRIMUS PHARMACEUTICALS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.